Compare Liberty Media Corporation Series C Liberty Formula One Common Stock (FWONK) vs NeoGenomics Inc. Common Stock (NEO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Liberty Media Corporation Series C Liberty Formula One Common Stock vs NeoGenomics Inc. Common Stock — how do they compare? Liberty Media Corporation Series C Liberty Formula One Common Stock trades at $90.85 (market cap $23.11B), while NeoGenomics Inc. Common Stock trades at $16.85 (market cap $2.14B). The key difference: Liberty Media Corporation Series C Liberty Formula One Common Stock is far larger — about 10.8× NeoGenomics Inc. Common Stock's market cap, and NeoGenomics Inc. Common Stock is trading nearer its 52-week high, Liberty Media Corporation Series C Liberty Formula One Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Liberty Media Corporation Series C Liberty Formula One Common Stock for 0 Days and NeoGenomics Inc. Common Stock for 0 Days on average.
| FWONK | NEO | |
|---|---|---|
Market Cap | $23.11B | $2.14B |
Volume | 3,394,596 | 2,228,400 |
Sector | Media | Health |
52-Week High | $106.66 | $19.91 |
52-Week Low | $81.42 | $7.19 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $26.57B | $2.44B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Liberty Media Corporation Series C Liberty Formula One Common Stock
Liberty Media Corporation's Series C Liberty Formula One common stock is a tracking stock reflecting the economic performance of the Formula One Group, which holds Liberty Media's interests in Formula 1 racing, MotoGP, and related minority investments.
Read more on FWONK →About NeoGenomics Inc. Common Stock
NeoGenomics, Inc. is a US cancer diagnostics company that provides genomic and pathology testing services, offering an oncology-focused testing menu used by oncologists, pathologists, and hospital systems across the cancer care continuum.
Read more on NEO →
